http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
우두현 대한임상약리학회 2005 Translational and Clinical Pharmacology Vol.13 No.1
Drugs are one of the most common causes that induce galactorrhea, though other various factors such as hypothalamic-pituitary disorders, idiopathic causes and some systemic diseases are known to cause galactorrhea. Among the medications, antidepressants, antihypertensives, phenothiazine and H2-blocker are known as common causes of non-puerperal lactation. Paroxetine is a potent antidepressant of SSRI (selective serotonin reuptake inhibitor) class, and there are few reports of galactorrhea induced by paroxetine. We experienced two cases of galactorrhea following treatment with paroxetine. In the first case, a 24-year-old woman, who took daily 10 mg paroxetine for her depression, developed galactorrhea four months later. Paroxetine was maintained because her depression continued. Thus bromocriptine, a dopamine agonist, was added to her regimen. The galactorrhea ceased approximately four weeks after the bromocriptine started. Thereafter paroxetine and bromocriptine were discontinued, and galactorrhea ceased. In the second case, a 30-year-old woman taking 10~20 mg paroxetine daily to treat her post-traumatic syndrome, developed galactorrhea three months later. The medication was discontinued the next morning and the discharge ceased three weeks later. Both of the patients showed normal findings of brain MRI and their serum prolactin levels are 5.7 ng/mL and 7.5 ng/mL respectively. They all revealed hypersensitivity in TRH stimulation test.
송란 ( Ran Song ),우두현 ( Doo Hyun Woo ),이연아 ( Yeon Ah Lee ),이상훈 ( Sang Hoon Lee ),이향이 ( Hyang Ie Lee ),신준범 ( Joon Beom Shin ),홍승재 ( Seung Jae Hong ),한정수 ( Chung Soo Han ),유명철 ( Myung Chul Yoo ),양형인 ( Hyu 대한내과학회 2007 대한내과학회지 Vol.73 No.2
Background: This retrospective study was performed to investigate the clinical effects of mizoribine with using methotrexate (MTX) or mizoribine alone on those patients with rheumatoid arthritis (RA) who showed an ineffective response or intolerance to the MTX. Methods: The patients were divided into two groups: (1) combination therapy of mizoribine with MTX and (2) mizoribine alone. All the patients took 100 mg mizoribine daily for at least 16 weeks. Before and after administration of mizoribine for 16 weeks, we assessed the clinical variables such as the visual analogue pain scale (VAS), the tender joint counts (TJC), and the swollen joint counts (SJC). At each time, the laboratory parameters including the ESR, CRP, complete blood count (CBC), liver enzymes and creatinine were also measured. Disease activity scores (by the DAS28) and the adverse effects were determined at baseline and after 16 weeks. Results: Fifty patients were recruited in this study (mizoribine plus MTX group: n=35, mizoribine group: n=15). There were no significant differences in the initial laboratory values between the two treatment groups. After treatment for 16 weeks, the DAS28 was decreased significantly in the mizoribine plus MTX group (4.7±1.14 vs. 3.9±0.97, respectively, p<0.05). Yet the mizoribine alone group did not showed any significant change of the DAS28 (4.3±0.56 vs. 3.9±0.37, respectively, p=0.076). Mild gastrointestinal disturbance was the most common adverse effect. The incidence of adverse effects was similar in both treatment groups (20% vs. 27%, respectively). Conclusions: Mizoribine in combination with MTX was effective for RA patients who showed an ineffective response or intolerance to MTX. Furthermore, this treatment can be considered to be relatively safe.(Korean J Med 73:192-199, 2007)